Earnings ·
Can-Fite BioPharma Ltd. reported H1 2026 financial results showing a net loss of $4.6 million, compared to $4.87…
CANFCan-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. reported H1 2026 financial results showing a net loss of $4.6 million, compared to $4.87 million in the prior year period. Revenues remained flat at $0.2 million, while R&D expenses increased by 13.9% to $3.45 million and G&A expenses decreased by 31.4% to $1.42 million. The company raised approximately $4.0 million in gross proceeds from the exercise of existing warrants under an inducement agreement executed on March 4, 2026. Clinically, the pivotal Phase III study for Namodenoson in hepatocellular carcinoma showed longer-than-anticipated overall survival, prompting an evaluation for earlier interim analysis. The company also completed enrollment in its Phase III psoriasis trial for Piclidenoson and announced a definitive agreement on September 2, 2026, to immediately exercise outstanding warrants at a reduced price of $2.50 per ADS. Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company developing small molecule therapeutics targeting oncological and inflammatory diseases.